Süleyman BADEMLER, Merve Müge ÜÇÜNCÜ, Murat SERİLMEZ

IGF-1 ve IGFBP3’ün Özofagus Kanseri’nin Tanı ve Tedaviye Yanıtındaki Yerinin Araştırılması

Amaç: Özofagus kanseri dünya genelinde tüm kanserler arasında sekizinci sırada yer almaktadır. Tüm kanserlerin % 1,5–2'sini, sindirim sistemi kanserlerinin ise % 5-7'sini oluşturmaktadır. Bu kanser türünde erken tanı, erken tedavi ve yakın takiple mortalite azaltılabilmektedir. Ancak erken tanı konabilmesi için erken tanıda kullanılabilecek hızlı sonuç alınan, güvenilir belirteçlere ihtiyaç vardır. Çalışmamızda özofagus tümörünün erken tanısı için IGFBP3 ve IGF-1’in kullanılabilirliğini araştırmayı amaçladık.

Anahtar Kelimeler:

Özofagus kanseri, IGF-1 seviyesi, IGFBP-3 seviyesi, erken tanı, tümör marker, sindirim sistemi kanseri

An Investigation into the Role of IGF-1 and IGFBP3 in the Diagnosis and Treatment Response in Esophageal Cancer

Aim: Esophageal cancer (EC) is the eighth most common cancer among all cancers worldwide. It constitutes 1.5-2% of all cancers and 5-7% of gastrointestinal cancers. Mortality reduction by early diagnosis, early treatment, and close follow-up is possible in esophageal cancer. However, reliable markers that rapidly provide results for early diagnosis are necessary in order to make such a diagnosis. In our study, it is aimed to investigate the role of IGFBP3 and IGF-1 in the early diagnosis of esophageal tumors.

Keywords:

Esophageal cancer İGF 1 levels, İGFBP3 levels, serum, early diagnosis, tumor marker, gastrointestinal system cancer,

PDF

___

Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400-412. doi: 10.1016/S0140-6736(12)60643-6
National Cancer Insti¬tute. SEER Cancer Statistics Review, 1975-2013. Based on November 2015 SEER data submission, posted to the SEER website, April 2016. https://seer.cancer.gov/archive/csr/1975_2013/ Accessed September 21, 2018
Short MW, Burgers KG, Fry VT. Esophageal cancer. American Family Physician. 2017;95(1):22-28. PMID: 28075104
Rahman OA. Insulin-like growth factor pathway aberrations and gastriccancer; evaluation of prognostic significance and assessmentof therapeutic potentials. Medical Oncology. 2015;32(1):431. doi: 10.1007/s12032-014-0431-8
Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. The Lancet Oncology. 2002;3(5):298-302
Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature Reviews Cancer. 2004;4(7):505–518. doi: 10.1038/nrc1387
Bademler S, Sarı M, Üçüncü MZ, Serilmez M, Karabulut S. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth binding protein-3 (IGFBP-3) in patients with gastric cancer. Acta Medica Mediterranea. 2018;34:2055-2061 doi: 10.19193/0393-6384_2018_6_320
Bademler S, Zırtıloğlu A, Sarı M, Yasasever CT, Karabulut S. IGF-1 AND IGFBP-3 in colorectal cancer, an observational case-control study. Acta Medica Mediterranea. 2019;35:15-21. doi: 10.19193/0393-6384_2019_1_1
Li H, Batth IS, Qu X, et al. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGFIR therapy: overview and new insights. Molecular Cancer. 2017;16(1):6 doi: 10.1186/s12943-016-0576-5
Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Research. 2005;65(22):10123–7. doi: 10.1158/0008-5472.CAN-05-2752
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer Journal for Clinicians. 2012;65(2):87-108. doi: 10.3322/caac.21262
Varghese TK Jr, Hofstetter WL, Rizk NP, et al. The Society of Thoracic Surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Annals of Thoracic Surgery. 2013;96(1):346-56. doi: 10.1016/j.athoracsur.2013.02.069
Ajani JA, D'Amico TA, Almhanna K, et al. National comprehensive cancer network. Esophageal and esophagogastric junction cancers, version 1.2015. Journal of The National Comprhensive Cancer Network. 2015;13(2):194-227. doi:10.6004/jnccn.2015.0028
Rustgi AK, El-Serag HB. Esophageal carcinoma. The New England Journal of Medicine. 2014;371:2499-2509. doi: 10.1056/NEJMra1314530
Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Annals of Surgical Oncology. 2010;17(7):1721-4. doi: 10.1245/s10434-010-1024-1.
Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7-42. doi: 10.1136/gutjnl-2013-305372.
Smithers BM, Gotley DC, Martin I, Thomas JM. Comparison of the outcomes between open and minimally invasive esophagectomy. Annals of Surgery. 2007;245(2):232–240. doi: 10.1097/01.sla.0000225093.58071.c6
Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Molecular Pathology. 2001;54(3):145–148. doi: 10.1136/mp.54.3.145
Adachi Y, Nojima M, Mori M, et al. Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study. World Journal of Gastroenteroly. 2017;23(19):3488-3495. doi: 10.3748/wjg.v23.i19.3488
Li J, Wang A, Song L, Zhao J. Expressıon and clinical significance Of AEG-1, E-Ca And IGFBP-3 in esophageal cancer patients. Acta Medica Mediterranea, 2018;34:1671. doi: 10.19193/0393-6384_2018_6_256